65,437 trials
Hepatitis C, Chronic
Primary: Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT) — 81; 70; 75; 88 percentage of participants
Neurofibromatosis Type II
Primary: Radiographic Response — 0 participants
Myopia
Primary: Overall Comfort — 60.1; 43.6 units on a scale
Neuroblastoma
Primary: Number of Participants With Dose-limiting Toxicity as a Measure of Tolerability — 0; 0 participants with DLT
Stroke
Primary: Fugl-Meyer Assessment. — 38.32; NA; 47.6; NA units on a scale
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia
Primary: Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions — 83.2; 81.6; 69.1; 91.2 percentage of…
Essential Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -18.21; -20.18; -13.20 mmHg
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Number of Participants With All Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 282; 28 participants
Allergic Conjunctivitis
Primary: Mean Change From Baseline in Ocular Redness, Area Under the Curve From Time Zero to Hour 10 [AUC (0-10)] at Day 7 — -2.8; -4.7; -8.1; -4.5 hours x units on a scale
Leukemia
Primary: Event-free Survival — 64.9; 70 percentage of participants
Non-Hodgkin's Lymphoma
Primary: Stage I: Trough Serum Concentrations (Ctrough) of IV and SC Rituximab — 83.1; 134.6 micrograms per milliliter (mcg/mL)
End Stage Renal Disease (ESRD)
Primary: Number of Participants With Serious Infectious Complications Following Transplantation — 2 participants
Recurrent Endometrial Carcinoma
Primary: Tumor Response — 24.5 percentage of participants
Opioid Related Disorders · Pregnancy · Opioid Dependence
Primary: Child's Head Circumference Measurement (Measured at Birth) — 33.0; 33.8 cm
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) · Adult Acute Promyelocytic Leukemia (M3) · Myelodysplastic Syndromes
Primary: Response Rate for Subjects Without FLT3 ITD Mutation — 16.67 percentage of participants